Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Published:2016-04 Issue:10028 Volume:387 Page:1629-1637
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Schöffski Patrick,Chawla Sant,Maki Robert G,Italiano Antoine,Gelderblom Hans,Choy Edwin,Grignani Giovanni,Camargo Veridiana,Bauer Sebastian,Rha Sun Young,Blay Jean-Yves,Hohenberger Peter,D'Adamo David,Guo Matthew,Chmielowski Bartosz,Le Cesne Axel,Demetri George D,Patel Shreyaskumar R

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. WHO classification of tumours of soft tissue and bone;Fletcher,2013

2. Soft tissue sarcoma. Version 1,2015

3. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease;Schöffski;Oncol Res Treat,2014

4. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions;Mastrangelo;Cancer,2012

5. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project;Stiller;Eur J Cancer,2013

Cited by 648 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A 24-kilogram retroperitoneal liposarcoma surgical management: A case report;Surgery Case Reports;2024-11

2. Translation of oncolytic viruses in sarcoma;Molecular Therapy: Oncology;2024-09

3. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

4. Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy;BMC Cancer;2024-08-20

5. Setting the international research agenda for sarcomas with patients and carers: results of phase II of the Sarcoma Patient Advocacy Global Network (SPAGN) priority setting partnership;BMC Cancer;2024-08-06